Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

PHASE3RecruitingINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

February 25, 2040

Study Completion Date

February 25, 2040

Conditions
Hemophilia AHemophilia B
Interventions
DIAGNOSTIC_TEST

Testing of hepatic AAV Vector integration

Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated

Trial Locations (12)

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

10065

RECRUITING

Weill Cornell Medical College-New York Presbyterian Hospital, New York

19104

RECRUITING

The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia

33612

RECRUITING

USF Health Morsani Center For Advanced Healthcare, Tampa

35100

RECRUITING

Ege Universitesi Hastanesi, Izmir

39110

TERMINATED

Mississippi Center For Advanced Medicine, Madison

94143

NOT_YET_RECRUITING

UCSF Outpatient Hematology Clinic, San Francisco

95816

RECRUITING

UC Davis Health, Sacramento

95817

RECRUITING

UC Davis Ambulatory Care Clinic, Sacramento

RECRUITING

UC Davis Hemophilia Treatment Center, Sacramento

RECRUITING

UC Davis Medical Center, Sacramento

98101

NOT_YET_RECRUITING

Washington Institute for Coagulation, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05568719 - Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively | Biotech Hunter | Biotech Hunter